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halamydia
trachomatis (C.t.) has been involved in
variety of pathological conditions ofthe female
and male genital tracts. Chronic female persistent
infections due to this micro-organism have been
recently investigated, but the role of C.t. has not
been completely clarified especially in acute and
chronic pathologies of the male genital tract.
The immunocompetency ofthe female and male
genital tract is well documentedl,Z; the production of
secretory IgA (SIgA) can take place in the fallopian
tubes, uterine cervix and vagina, prostate and the
epididymis, resulting in local production of SIgA
by submucosal plasma cells present in a quantity
greater than plasma cells producing IgM and IgG.
During infections, increased numbers ofthese three
classes of plasma cells are present. Specific SIgA
against various infectious agents, such as Escherichia
coli and Chlamydia trachomatis,4’5’6 are produced in
pathological conditions of the genital tract.
SIgA mediates the protection of mucosal mem-
brane by interfering with microbial adherence to
mucosal surfaces and by inhibiting the penetration
of potentially harmful micro-organisms into muco-
sal tissues. IgA occurs in serum and secretions as
two subclasses that differ in amino acid sequences
and glycosylation of the ot heavy chain. IgA1 pre-
dominates in serum whereas secretions may contain
up to 60% IgA2. Subclass composition and response
may be important parameters in understanding the
host immune response, but the physiological signif-
icance ofthe two subclasses has not been explained.
It has been postulated that IgA1 and IgA2 antibod-
ies may play different protective roles: IgA1 is sus-
ceptible to bacterial IgA1 proteases; the degrading
effect of the IgA1 protease from N. gonorrhoeae
on anti sperm antibodies suggested a predominant
local IgA1 response at least to some antigens but
the actual in vivo situation has never been proved.
The role of IgA1 proteases has been demonstrated
in relation to dental flora: they may promote the
adherence of oral streptococci to tooth surface. In
1992, a very strong SIgA protease was demonstrated
to be associated with the spermatic fraction of hu-
man semen. IgA2 is protease resistant and plays a
true role in mucosal defense. The subtle functional
differences between IgA1 and IgA2 became re-
cently apparent but, their biological effective role
is not clarified.
The appearance of elevated SIgA in seminal
plasma, especially during infections, seems to be
related to a pathological rather than a physiological
situation of the male genital tract. The overproduc-
tion of SIgA could be theoretically explained by
release ofcytokines such as interferon y, interleukin
(IL) 4 and 5, and tumor necrosis factor (TNFot), as
demonstrated in the gastrointestinal tract. Other-
wise, recently, TNFot, and, more recently, other
LPS induced cytokines, IL-1 and IL-6, were shown
*Address correspondence to Sandra Mazzoli, P.H.D., Specialist in Microbiology, S.T.D. Centre Coordinator and S.T.D.
Laboratory Responsible, S.T.D. Centre, Infectious Disease Unit, S.M. Annunziata Hospital, U.S.L. 10H, Via dell’Antella
58, Antell, 50111 Florence, Italy.
Article
Received September 15, 1996
Accepted October I, 1996CLINICAL CT INFECTION 1NMEN MAZZOLI ET AL.
to be present, in vivo,
1 in mice infected by MoPn
Chlamydia trachomatis biovar, enhancing a protective
role against the infection. TNFOt may play a deter-
minant role in other cytokine pathways, leading to
enhanced host defence and it is involved in the T-
cell independent pathway of macrophage activa-
tion. Its production has been recently demonstrated
as proportional to the intensity of the infection
with high levels coincident with marked neutrophil
influx. 11 Cytokines are important mediators of in-
flammation and their production may modulate im-
munity during Chlamydia trachomatis infections as
proved by recent in vitro studies. The role of their
induction, especially for IL-1 and IL-6, is actually
unclear during several infections. A recent paper
1
concluded that ILl and IL6 production in vivo in
mice could play a role in the pathogenesis and host
defence of Chlamydia trachomatis infection. Addi-
tionally the immune response to Chlamydiae may be
immunopathological, as was demonstrated in 1969
in trials oftrachoma vaccination in children in Gam-
bia13 in which the severity of the disease in terms of
clinical score was paradoxically greater in vaccinated
than in unvaccinated controls. In addition, mice sen-
sitized by immunization with a crude extract or with
chlamydial heat shock protein suffered more severe
inflammation when challenged intravaginally with
live mouse pneumonitis agent organisms.
The cytokine content of patients’ biological flu-
ids may be a good indicator ofthe possible evolution
and shift of the immune response, TH1 or TH2,
mediated by IFN/ and IL-12 or IL-4. The
TH1 Th2 shift itself may be involved in immu-
nopathological conditions of the genital tract during
Chlamydia infections, as demonstrated in human im-
munodeficienc virus pathogenesis studies in
vitro. 14’5 Several recent studies suggest that TH
cells are crucial in the resolution of established
Chlamydial infections.4,5 Additionally C. tracho-
matis was demonstrated to induce IL-8 secretion in
in vitro infected HT29 cells, independent of ILia
stimulation.6 IFN/affects the IL-8 induction path-
way that does not involve ILlot. This suggests that
T-cell-derived cytokines may also control the host
response to Chlamydia by altering the ability ofnon-
immune cells to respond to the infection, by secre-
ting proinflammatory cytokines and thus increasing
the number of inflammatory cells at the site of
infection. Cellular immunity is, on the other hand,
important in resolving and eradicating established
chlamydial infections and pre-existing anti-MOMP
antibodies are unable to protect against inital muco-
sal colonisation (25). In addition IL-10 is the major
inhibitor of TH1 responses and of INF,/.
OBJECTIVE OF THE STUDY
Starting with the previous evidence and the obser-
vation of inflammatory symptoms in acute and
chronic prostatitis patients, we investigated sera and
mucosal secretions for the presence of IL-6 and
other cytokines (IL-4, IL-10) in relation to anti-C.t.
IgA and IgG and to IgA subclasses in seminal fluids
of selected men affected by "abacterial" prostatitis.
In addition we studied the concomitant presence
of chlamydial DNA by PCR techniques; the global
aim of our study was to possibly interrelate all these
immunological parameters with the pathological sit-
uation and progression to chronicity in our patients.
MATERIALS AND METHODS
Our study population of 28 patients was selected
starting from 290 outpatients admitted to our S.T.D.
Centre, Infectious Diseases Unit, S. M. Annunziata
Hospital, Florence Italy; the patients were affected
by prostatitis or prostatovesciculitis.
The prevalence of anti C.t. specific SIgA in this
population was 46.5% (135 positives). The patients’
study inclusion criteria were the presence of acute
or chronic prostatitis or prostatovesciculitis, clini-
cally and echographically documented, the pres-
ence of a strongly positive screening test for species
specific anti C.t. IgA in seminal fluids and serum.
Exclusion criteria were the presence of myco-
plasmata, bacteria, protozoa, fungi in first morning
urine and seminal fluids; negativity for sperm IgA,
and antibiotic therapy carried out in the previous
six months.
18/28 (64.2%) patients declared symptoms in the
past 3 years and 4/28 patients (14.28%) for at least
5 years. All had symptoms since at least six months.
Other signs and symptoms were present: prostatic
microcalcifications, urethral discharge, stanguria,
hematuria, perineal tenesmus, groin, pelvic or ejac-
ulation pains, lymphoadenopathy. Previous S.T.D.
infections were mainly H.P.V. infections (10/28).
Patients ranged from 26-73 years old with a mean
age of 39.1; 85% of patients were between 26-50
years old.
The patients’ biological materials that were ana-
lysed were sera, semen and urethral swabs. Immedi-
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ately after sampling, sera were centrifuged and fro-
zen at -40C, if not immediately tested. To obtain
idoneous urethral samples patients were required to
return to the laboratory on at least 3 different subse-
quent days for 3 different samples: slides for Direct
Immunofluorescence obtained by endourethral
swabs, swabs in the idoneous transport medium for
the ELISA test and samples from urethra for
Amplicor PCR. All samples were immediately eval-
uated by the 3 methods. Our diagnostic protocol
included a search for C.t. in patients’ urethra by DIF
(Bio Merieux, France), ELISA (Abbott Diagnostics,
USA), and Amplicor Chlamydia trachomatis PCR
(Roche Diagnostic System, Switzerland), a new sen-
sitive and specific test on this sample, z3
Semen was aliquoted for the various tests ac-
cording to the sample amount by the following de-
scribed procedures and frozen at -40C until
assayed.
PCR on semen was performed by a modified
Amplicor PCR. DNA recovery from semen samples
was performed by 2 different methods. DNA was
extracted from seminal fluids utilising the QIAamp
Tissue Kit for rapid purification of DNA for PCR
amplification tests. This method was the most effi-
cient procedure for extracting DNA from semen.
It provided rapid purification of up to 50 txg of
DNA from 200 txl of body fluids. Our modification
of the original Amplicor PCR procedure consisted
of using for each amplification 50 txl master mix,
50 1 of extracted DNA and 10 txl 25mM MgClz.
Cell Culture
Vero cells (African green monkey kidney) were
grown in 150 cm tissue culture flasks (Falcon) with
199 medium (Biochrom, KG) supplemented with
5% heat inactivated calf fetal serum (Seromed),
0.22% NaHCO3 and 50 Ixg/ml ofgentamicin at 37C.
The cells used in the culture were negative for
mycoplasmas. When the cell monolayer was conflu-
ent, the growth medium was removed and the
monolayer was trypsinized. Cells were suspended
in growth medium and counted in a Burker glass
chamber. For the assay 2 x 103 cells per well were
seeded into a 24 well tissue culture plate (Falcon)
containing cover slips. The culture was incubated
at 37C for 24 hours in a COz incubator. The infec-
tion of the cells was performed by aspirating the
culture medium and replacing it with Eagle’s mini-
mum essential medium (MEM) supplemented with
10% fetal calf serum 0.17% NaHCO3, 0.4% glucose,
50 g/ml gentamicin, g/ml cyclohexamide
(Sigma) containing Chlamydia trachornatis serotype
LGV2-434 Bu strain at 1-5 inclusion forming units
per cell, to insure infection of 80% of the cells. The
infected cultures were incubated at 36.5C for 48
hours in a 5% COz thermostat. At this time 50-80%
of the cells showed typical cytoplasmic inclusions
detectable by phase-contrast inverted microscopy
and stains. The medium was then aspirated and
the cells washed 2 times with phosphate-buffered
saline (PBS). The cover slips were fixed for 10 min-
utes with methyl alcohol cooled to -10C, dried
and kept at -20C before use as antigens in indirect
immunofluorescence test to detect anti-chlamydial
secretory IgA.
Specific anti C.t. immunoglobulins of the G, A
classes were detected in semen and sera by Indirect
Immune Peroxidase (liP) test (IPAZyme, Savyon
D. Ltd., Israel), Microimmunofluorescence (MIF)
test (Labsystem, Finland), ELISA tests (SeroElisa
by Savyon D. Ltd., Israel) and Chlamydia rElisa
(Medac Diagnostika, Germany). In the present
study, we used as antigens to detect specific anti
C.t. SIgA both the purified elementary body (MIF)
and whole cells infected by this organism: McCoy
cells (Savyon) or Vero cells (our original culture)
infected by LGV2 C.t. serotype. Secretory compo-
nent, IgA1 and IgA2 were detected by an original
indirect immunofluorescence technique utilising
fluorescine isothiocyanate labeled polyclonal anti-
bodies (Dakopatts, Denmark; The Binding Site
Ltd. U.K.). Biological material under study were
absorbed with the various antigenic substrates for
30 minutes at 37C in a humid chamber; after wash-
ing in PBS for at least 10 minutes, the fluorescine
conjugate was absorbed for 30 minutes at 37C.
Testing dilutions of the conjugates were made in
accordance with the manufacturers’ recommenda-
tion. Negative and positive controls were run with
each reaction. A final washing step was performed
in PBS and observation was immediately done un-
der fluorescence microscopy at 40x magnification:
secretory component showed a fine diffuse fluores-
cence positivity which was confirmed in immersion
fluorescence microscopy at 100 magnification.
Interleukin Assays
IL-6 was detected by a quantitative ELISA method
(Eurogenetics, Belgium) utilising anti-IL6 mono-
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clonal antibodies. Blood samples were collected in
Vacutainer B.D. glass tubes and left to sediment
hour at room temperature before centrifuging the
samples (1700 g., 30 min., 4C). We collected the
upper two-thirds of the supernatants (1 ml) and
stored at -40C until assayed. Serum samples were
aliquoted and one aliquot was decomplemented (20
min. 56C.) before testing to destroy the possible
interfering action of the soluble IL-6 receptor,
which binds IL-6 in solution. Bioassays of sera were
performed in duplicate to verify if increments of
the concentration could be present in the decom-
plemented fraction. Quantification of the IL-6 con-
tent was performed by using five standards of 10,
25, 50, 200 and 500 pg/ml IL-6. The standards were
calibrated against the "Unclassified Interleukin-6
(recDNA human type) 88/514". One vial containing
ng lyophilised IL-6 was used as a recovery control
positive test and was reconstituted with a negative
semen. Normal values in our population were pre-
viously calculated for semen starting from a selected
normal population negative for signs and symptoms
of prostatitis and for all bacterial, mycoplasmal and
other microbial infections. IL-4, IL-10 were de-
tected by quantitative ELISA tests (Biokine, T-
cell Diagn. Inc. and Predicta Genzyme, USA).
Statistical Methods
The Wilcoxon test for paired data was used to deter-
mine the comparison between the detected values
of all our immunological parameters by Labstat ver-
sion 3.03 program for Biostatistic. MS DOS SyStat
program and SysGraph for Window were used for
statistical analysis and graphics.
RESULTS AND DISCUSSION
Specific anti Chlamydia trachomatis IgA was a con-
stant component in patients’ seminal fluids by all
our methods of detection; both of the ELISA tests
detected a very high content of IgA with 75% agree-
ment for absorbance values over 2.000. Statistical
analysis on IgA means (SeroELISA test and Medac
r-ELISA) obtained in semen and sera, revealed sta-
tistically significant differences (p 0.000), re-
flecting local overproduction of IgA in semen and,
thus, in tissues.
Higher levels of anti LPS IgA detected in semen
was in accord with animal studies in which the
persistence and recovery of high levels of IgA in
secretions of the genital tract seem to be related to
a booster16 effect only at the site of infection. Thus,
in prostatitis patients this could be related to the
persistence of the infection in the male upper geni-
tal tract.
The recombinant anti-LPS test showed the pres-
ence of a higher level of anti-LPS specific anti C.t.
antibodies of both the two classes: IgA and IgG.
Semen IgG against C.t. LPS were demonstrated in
12 patients by rELISA as compared with 5 patients
by SeroElisa; IgG detection in seminal fluids was
important to verify if the local immunisation in
these patients was locally produced or a translocated
extension of humoral immunity, transudated from
sera. IgA1, IgA2 subclasses were detected in semi-
nal fluids and sera of all 28 patients except 2: IgAl
was demonstrated in semen of 8/28 patients
(28.5%). 93.7% of the patients declaring symptoms
in the previous 3 years were positive for IgA2, mak-
ing IgA2 immune response strictly related to the
persistence of the infections. IgA2 was mainly pres-
ent in our patients (92.8%) confirming, as in our
previous observations, their presence as the most-
expressed and significant immunoglobulin subclass
in semen. These data seem to be in agreement with
the production of IgA1 proteases in this biologic
fluid. Otherwise, the presence of IgA1, in the major-
ity of the semen samples containing detectable lev-
els of IgG, seems to correlate well with the possible
transmembrane translocation or transudation of se-
rum IgG, probably due to permeability damages of
the blood-genital tract barrier, caused by inflamma-
tion and its powerful mediators.
IL-4 was also assayed but this lymphokine was
not detectable. IL-10 was present in high levels in
75% (25/28) of our patients and very high values
were present in IgA2 positive patients.
IL-6 was present at a fourfold higher concentra-
tion (>20 pg/ml) than normal serum levels (5 pg/
ml) in 75% (21/28) of our selected patients seminal
fluids. Comparison of IL-6 detected in sera and
semen showed a statistically significant difference
(p 0.001) between mean concentrations, in favour
of a local overproduction of this cytokine. Ifwe plot
IL-6 (semen) vs. IgG and IgA detected (Savyon
SeroElisa.) in semen of our patients we obtain Fig-
ure 1; IL-6 values were distributed in three groups
on the IgG axis. The majority of our IgG detection
coincided with no IL-6 or with very low values, a
smaller group in proximity of the cut-off and sparse
observations on higher values. Observing the distri-




Fig. I. In asciss axes the Optical Densities (O.D.) of the
IgG and IgA (from 0 up to fictitious value 4.000; real values
detected till 3.000) detected in semen of our patients by
SeroELISA test; in ordinate axis IL-60.D. It is possible to
distinguish three different subpopulations: the first one with
zero values of IgG and medium values of IgA, the second
one with very high values of IgA and zero values of IgG and
the third one with very high values of IgA and high values
of IgG; included in the last one are the IgAI positive patients,
showing contemporary presence of IgG and IgAI subclass
antibodies probably of serum origin through a transmem-
brane translocation process.
bution from the IgA axis’ point of view, we have a
first group aligned on the 3.000 optical density value
(fictitious value attributed to values read as "Over",
by ELISA test). This group contains also the higher
values of IL-6, roughly as far as 2100 value for IgG.
A second group defines patients under O.D. 2.000
and lower.
Secretory component ofthe IgA was investigated
by using different antigens. The presence of 3 nega-
tive patients utilising purified EB. of C.t. LGV2
serovar, may be explained with the possibility of
the lack of 20% specific immunization utilising one
single C.t. serotype, or, more likely, with the pres-
ence of polymeric IgA against different antigens,
or with the presence of monomeric IgA in semi-
nal fluids.
Otherwise, 89.2% of these patients had evidence
of secretory component. Thus the IgA immune re-
sponse was a secretory related response. Mucosal
surfaces in direct contact with the external environ-
ment, including the genital tract, have a common
immune system with selective traffic of B and T
lymphocytes fromGALT and BALT. 16The specific
anti C.t. response in our patients is independent of
the response in serum and mostly associated with
secretory IgA.
It was not possible to interrelate chlamydial
DNA positivity with other markers of infection,
because of the negative PCR results obtained in
seminal fluids; we can only affirm that 28.5% (8/
28) of our patients were PCR positive for C.t.DNA,
confirming the presence of the micro-organism as
a possible "primum movens" of the pathology and
its presence. Another reason for negative PCR re-
suits could be the presence of very high values of
SIgA: our finding seems to confirm animal model
findings 17 in which an inverse correlation between
specific SIgA titre in genital secretion and the pres-
ence of Chlamydia trachomatis isolated by culture in
the cervix was found.
CONCLUSIONS
We conclude that our patients with anti Chlamydia
trachomatis IgA positive "abacterial" prostatitis have
"Chlamydial" prostatitis; they presented with spe-
cific local immunisation against this microorganism,
a local overproduction of IgA confirming the proper
immunocompetency of the genital tract, indepen-
dent from the systemic humoral one, probably not
protective (prevalence of DNA detection at a high
rate) and continuously boostered by antigen elimi-
nation. Induction of IgA2 seems to be strictly re-
lated to the persistence of symptoms and, thus, of
infection. Moreover, IgA2 is related to the type of
antigenic stimulation
18 at the mucosal site and to
repeated antigenic stimulation, more than to a bio-
logical shift in local IgA production, caused by
destruction of IgA1 by bacterial proteases. This hy-
pothesis seems to find confirmatory reports in a
recent paper of Kawamura and co-workers,
19 dem-
onstrating that the ancestral ot chain genes are
closely related to the ot 2 and not ot ones ofhumans
and hominoid primates. Future studies will be ex-
tremely useful in expanding our understanding of
the biological role of these antibodies.
The presence of IgA2 in the case of chronic
prostatitis in our population is a confirmatory
marker of the persistence and pathology ofthe chla-
mydial infection. Secretory IgA themselves, in se-
men of our chronic prostatitis patients (symptoms
since 3-5 years to at least 6 months), is an index of
"active" infection and allows us to detect and to
define "chronic active infections" of the prostate.
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Our patients presenting with chronic prostatitis
were very rich in symptoms, mainly those with cor-
responding high levels of secretory IgA in seminal
fluids, confirming that anti C.t. IgA total content
and SIgA concentration is a reliable index of infec-
tious activity. These reports are, in addition, empha-
sized by the contemporary association of elevated
values of IL-6, whose importance in inflammatory
phase processes is well known,z
The local production of IL-6 is well documented
in our patients affected by prostatitis. Thus, we
can confirm the production of this multifunctional
cytokine in human chlamydial infection in vivo.
IL-6 is strictly correlated to the anti Chlamydia tra-
chomatis secretory and total IgA content in seminal
fluids and doesn’t seem to affect this immunoglobu-
lin production, if not as a stimulatory factor. Like
in the mouseel IL-6 production may reflect the
CD4+ T cells helper function in genital tract muco-
sac by providing help to mucosal B cells for the
production of Chlamydia-specific IgA. IL-4 was not
detectable and this fact may be due to its rapid
turnover in body fluids or to the fact we can detect
only terminal TH2 cytokines. The recovery of
IL-10 in patients with chronic symptoms and IgA2
was extremely interesting. IL-10 is the major inhibi-
tor ofIFNy which induces inhibition ofChlamydial
growth in vitrozz’z3,z4 and resolution of Chlamydial
infections, z5 Thus the presence of IL-10 in our
chronic patients confirms that, in these patients too,
cell mediated immunity is depleted and the TH2
immune shift seems correlated with the persistence
of the infection and with the overproduction of IgA
antibodies and with the adverse pathological events
in the target organ, the prostate gland.
The biological role of IL-6, other cytokines and
secretory IgA overproduction in modulating the
passage from acute to chronic prostatic infection
and micro-organism clearance, is emphasized by our
findings, and the possibility that the pathogenesis
ofChlamydial prostatitis could be immune complex
related has to be thoroughly investigated in the
future.
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